Lubomı́r Elbl

664 total citations
39 papers, 330 citations indexed

About

Lubomı́r Elbl is a scholar working on Cardiology and Cardiovascular Medicine, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lubomı́r Elbl has authored 39 papers receiving a total of 330 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Cardiology and Cardiovascular Medicine, 13 papers in Oncology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lubomı́r Elbl's work include Chemotherapy-induced cardiotoxicity and mitigation (20 papers), Cancer Treatment and Pharmacology (10 papers) and Cardiovascular and exercise physiology (7 papers). Lubomı́r Elbl is often cited by papers focused on Chemotherapy-induced cardiotoxicity and mitigation (20 papers), Cancer Treatment and Pharmacology (10 papers) and Cardiovascular and exercise physiology (7 papers). Lubomı́r Elbl collaborates with scholars based in Czechia, United States and Germany. Lubomı́r Elbl's co-authors include Hana Hrstková, Jaroslav Michálek, Jan Mužı́k, Jaroslav Benedı́k, Vladimı́r Znojil, Jiřı́ Vácha, Jiří Vorlíček, Petr Beneš, Anna Vašků and Milan Navrátil and has published in prestigious journals such as Intensive Care Medicine, Critical Care and Journal of Molecular Medicine.

In The Last Decade

Lubomı́r Elbl

31 papers receiving 314 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lubomı́r Elbl Czechia 12 157 64 57 51 47 39 330
R. Stephen Krombach United States 10 314 2.0× 46 0.7× 35 0.6× 44 0.9× 53 1.1× 17 466
Ksenija Stach Germany 12 270 1.7× 23 0.4× 20 0.4× 23 0.5× 82 1.7× 37 506
Joshua J. Man United States 8 104 0.7× 22 0.3× 27 0.5× 51 1.0× 83 1.8× 13 380
Yukiko Fukuda Japan 10 107 0.7× 112 1.8× 17 0.3× 27 0.5× 84 1.8× 27 358
Karl-Johan Tötterman Finland 8 134 0.9× 25 0.4× 22 0.4× 43 0.8× 59 1.3× 10 321
Ben Corden United Kingdom 9 303 1.9× 43 0.7× 12 0.2× 40 0.8× 36 0.8× 11 407
Ching-Pei Chen Taiwan 10 87 0.6× 22 0.3× 39 0.7× 39 0.8× 54 1.1× 26 328
Lawrence R. Shoemaker United States 15 60 0.4× 68 1.1× 18 0.3× 92 1.8× 70 1.5× 35 520
Fıkret Akyürek Türkiye 12 43 0.3× 88 1.4× 38 0.7× 30 0.6× 23 0.5× 39 355

Countries citing papers authored by Lubomı́r Elbl

Since Specialization
Citations

This map shows the geographic impact of Lubomı́r Elbl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lubomı́r Elbl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lubomı́r Elbl more than expected).

Fields of papers citing papers by Lubomı́r Elbl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lubomı́r Elbl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lubomı́r Elbl. The network helps show where Lubomı́r Elbl may publish in the future.

Co-authorship network of co-authors of Lubomı́r Elbl

This figure shows the co-authorship network connecting the top 25 collaborators of Lubomı́r Elbl. A scholar is included among the top collaborators of Lubomı́r Elbl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lubomı́r Elbl. Lubomı́r Elbl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Valík, Dalibor, et al.. (2023). Revisiting treatment-related cardiotoxicity in patients with malignant lymphoma—a review and prospects for the future. Frontiers in Cardiovascular Medicine. 10. 1243531–1243531. 2 indexed citations
3.
Baťalík, Ladislav, et al.. (2013). Představení pilotního tréninkového programu pro pacienty shematoonkologickým onemocněním. 1 indexed citations
4.
Elbl, Lubomı́r, et al.. (2007). [Chronic fatigue syndrome in cancer patients. Diagnostic and treatment options].. PubMed. 53(9). 979–85. 1 indexed citations
5.
Kýr, Michal, et al.. (2007). Modeling effect of the septic condition and trauma on C-reactive protein levels in children with sepsis: a retrospective study. Critical Care. 11(3). R70–R70. 10 indexed citations
6.
Hrstková, Hana, Lubomı́r Elbl, Zuzana Nováková, et al.. (2006). Krevní tlak a funkce levé komory srdeční u pacientů léčenýchantracykliny. Klinicka onkologie. 19(5).
7.
Hrstková, Hana, Lubomı́r Elbl, Zuzana Nováková, et al.. (2006). EXERCISE TESTING IN CHILDREN AND ADOLESCENTS AFTER COMPLETING ANTHRACYCLINE ANTITUMOUR THERAPY. 79(5).
8.
Elbl, Lubomı́r, et al.. (2006). Evaluation of Acute and Early Cardiotoxicity in Survivors of Hodgkin's Disease Treated with ABVD or BEACOPP Regimens. Journal of Chemotherapy. 18(2). 199–208. 11 indexed citations
9.
Elbl, Lubomı́r, Ingrid Vášová, Zdeněk Král, et al.. (2006). Cardiopulmonary exercise testing in the evaluation of functional capacity after treatment of lymphomas in adults. Leukemia & lymphoma. 47(5). 843–851. 30 indexed citations
10.
Elbl, Lubomı́r, et al.. (2005). Remodelace levé komory srdeční u nemocných s akutním infarktem myokardu po absolvování ambulantního řízeného rehabilitačního programu. Cor et Vasa. 47(4).
11.
Elbl, Lubomı́r, et al.. (2005). Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients. European Journal of Pediatrics. 164(11). 678–684. 27 indexed citations
12.
Elbl, Lubomı́r, et al.. (2005). Rehabilitace po infarktu myokardu (II): způsoby zátěže. 3(2).
13.
Elbl, Lubomı́r, et al.. (2005). Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up. Supportive Care in Cancer. 14(2). 128–136. 23 indexed citations
14.
Elbl, Lubomı́r, et al.. (2003). The late consequences of anthracycline treatment on left ventricular function after treatment for childhood cancer. European Journal of Pediatrics. 162(10). 690–696. 36 indexed citations
15.
Elbl, Lubomı́r, et al.. (2003). Dynamic stress echocardiography in asymptomatic patients who received chemotherapy in childhood because of a malignant disease.. PubMed. 58(3). 190–6. 2 indexed citations
16.
Beneš, Petr, Jan Mužı́k, Jaroslav Benedı́k, et al.. (2001). The C766T low-density lipoprotein receptor related protein polymorphism and coronary artery disease, plasma lipoproteins, and longevity in the Czech population. Journal of Molecular Medicine. 79(2-3). 116–120. 20 indexed citations
17.
Beneš, Petr, Kateřina Kaňková, Jan Mužı́k, et al.. (2001). Methylenetetrahydrofolate Reductase Polymorphism, Type II Diabetes Mellitus, Coronary Artery Disease, and Essential Hypertension in the Czech Population. Molecular Genetics and Metabolism. 73(2). 188–195. 47 indexed citations
18.
19.
Elbl, Lubomı́r, et al.. (1998). Anthracyclines and the heart.. 7(4). 1 indexed citations
20.
Elbl, Lubomı́r, et al.. (1994). [Difficulties in the therapy of primary amyloidosis].. PubMed. 40(9). 595–9. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R. Stephen Krombach Breakdown of academic impact, for papers by Ksenija Stach Breakdown of academic impact, for papers by Joshua J. Man Breakdown of academic impact, for papers by Yukiko Fukuda Breakdown of academic impact, for papers by Karl-Johan Tötterman Breakdown of academic impact, for papers by Ben Corden Breakdown of academic impact, for papers by Ching-Pei Chen Breakdown of academic impact, for papers by Lawrence R. Shoemaker Breakdown of academic impact, for papers by Fıkret Akyürek
Rankless by CCL
2026